Great Basin Scientific Inc (NASDAQ:GBSN), a molecular diagnostics company, today announced the establishment of Great Basin Health Systems, a sales team formed to expand the Company’s sales efforts into previously untapped provider groups and networks searching for vendor partners to help them achieve improved patient care and lower patient costs. Heather Schram and Tamara Stojanovski, seasoned sales executives, will lead Great Basin Health Systems’ efforts.
“Hospitals greatly need our versatile, cost effective and easy-to-use molecular diagnostics solution, however too many are currently constrained from adopting Great Basin by purchasing systems that simply are not yet aware of Great Basin and the exceptional advantages our system can offer their hospitals,” said Sandra Nielsen, senior vice president of sales, marketing and human resources. “By engaging directly with these networks, we see a remarkable opportunity to reach more hospitals faster, which we believe will accelerate growth in our customer base and help hospitals improve patient outcomes while providing a valuable cost-savings for the hospital and hospital network. We’re thrilled to be able to introduce our system to a larger segment of the marketplace.”
In this new role, both Ms. Schram and Ms. Stojanovski will work with Group Purchasing Organizations (GPO), Integrated Delivery Networks (IDN) and Regional Purchasing Coalitions (RPC) as a vendor partner that can help achieve quality outcomes, while reducing total cost of care. Great Basin Health Systems will provide individual hospitals greater access to Great Basin’s technology through contracting at the group level, and creating strategies for long-term partnerships with groups and networks focused on achieving mutual objectives.
“We are excited to welcome Heather and Tamara—two extremely accomplished and respected sales executives—to Great Basin,” said Mike Blitz, vice president of U.S. Sales for Great Basin. “They represent the first phase of the Company’s aggressive Sales expansion objectives for the next 18 months and we look forward to this team introducing untapped markets to our unique and compelling business model that places our analyzer at no cost, allowing a hospital lab to adopt molecular diagnostic testing without any capital expenditure. That model, coupled with our expanding menu of tests and panels makes Great Basin a peerless molecular diagnostic solution to partner with for a variety of hospital groups and networks.”
Ms. Schram joins Great Basin from Acelity, a wound care and regenerative medicine company based in Texas, where she served as a national account director responsible for developing relationships to establish the company as a strong strategic partner for hospitals and healthcare systems. She also worked to maximize revenue and profitability through development of specialized programs with strategic customers including IDNs, GPOs, and RPCs. Prior to her work with Acelity, Ms. Schram served in a number of sales leadership positions, including director of national accounts at Meridian Bioscience, Inc. in Ohio, and territory manager at California-based Sage Products/BioSafety Systems. Ms. Schram earned a B.S. in business administration at University of Northern Colorado, completed a program on negotiation and leadership at Harvard Law School and has been recognized with numerous sales performance awards throughout her career.
Ms. Stojanovski comes to Great Basin having previously served as director of corporate accounts at Acelity, where she was responsible for developing strategies, tactics and contracts focused on accelerating product adoption and revenue growth in key IDNs. Through her tenure at Acelity, Ms. Stojanovski successfully delivered an impactful value message to appropriate stakeholders including supply chain, VAT directors, chief nursing officers, surgeons and GPOs. Ms. Stojanovski previously served as a regional director at Premier Healthcare Alliance in North Carolina, and as regional sales manager of the southwest region at Meridian Bioscience. Notably, Ms. Stojanovski obtained the first GPO contract for Meridian Bioscience for its then-new molecular platform. She earned her B.S. in advertising from University of Illinois, Champaign-Urbana, Ill., and received a full fellowship from the J.L. Kellogg Graduate School of Management, Northwestern in the department of marketing’s Ph.D. program.
Ms. Schram and Ms. Stojanovski will report to Mike Blitz. (Original Source)
Shares of Great Basin are currently trading at $1.54, $0.04 or 2.79%. GBSN has a 1-year high of $6720 and a 1-year low of $1.50. The stock’s 50-day moving average is $1.94 and its 200-day moving average is $7.89.
Great Basin Scientific, Inc. is a molecular diagnostic testing company, which focused on the development and commercialization of its patented, molecular diagnostic platform designed to test for infectious disease, especially hospital-acquired infections. Great Basin Scientific was founded by David C. Ward, Anthony R. Torres and David Spafford on June 27, 2003 and is headquartered in Salt Lake City, UT.